Case Control Study
Copyright ©The Author(s) 2020.
World Journal of Hepatology. Feb 27, 2020; 12(2): 34-45
Published online Feb 27, 2020. doi: 10.4254/wjh.v12.i2.34
Table 1 Baseline characteristics of the study population, n (%)
General characteristicsCases (n = 10)Controls (n = 20)
Female sex6 (60)12 (60)
Age (yr)56 ± 14.257 ± 12.9
BMI (kg/m2)25.57 ± 3.4427.30 ± 7.57
Lymphoma type
Hodgkin lymphoma1 (10)2 (10)
Non-Hodgkin lymphoma9 (90)18 (90)
Laboratory data
Hemoglobin (g/dL)12.13 ± 2.3911.97 ± 3.18
Platelets (K/μL)166.60 ± 143.8a293.9 ± 157.6
Leukocytes (K/μL)5.4 ± 1.797.47 ± 3.79
INR1.24 ± 0.19b1.0 ± 1.0
Total bilirubin (mg/dL)1.74 ± 1.31a0.97 ± 0.75
Direct bilirubin (mg/dL)0.76 ± 0.82a0.27 ± 0.34
ALT (U/L)31.82 ± 33.3025.6 ± 13.35
AST (U/L)48.50 ± 27.31a32.1 ± 16.52
Alkaline phosphatase (U/L)210.40 ± 261.2136.40 ± 149.1
Albumin (g/dL)2.78 ± 0.693.3 ± 0.82
Sodium (mmol/L)132 (130-138)137 (132-140)
Creatinine (mg/dL)0.82 ± 0.211.63 ± 2.25
β-2 Microglobulin (g/dL)3.17 ± 1.393.02 ± 3.08
LDH (U/L)198.29 ± 119.81356.5 ± 304.86
Comorbidities
Obesity2 (20)6 (30)
Dyslipidemia0 (0)4 (20)
Diabetes mellitus3 (30)3 (15)
Arterial hypertension2 (20)8 (40)
Alcohol consumption3 (30)5 (25)
Tobacco consumption5 (50)7 (35)
Rheumatoid arthritis0 (0)2 (10)
Table 2 Characteristics of the population with liver cirrhosis, n (%)
Characteristics of patients with cirrhosisCases (n = 10)
Etiologies of cirrhosis
HCV5 (50)
NAFLD2 (20)
Alcohol1 (10)
Autoimmune hepatitis1 (10)
Cryptogenic1 (10)
States of cirrhosis
Compensated2 (20)
Decompensated8 (80)
Events of decompensation
Jaundice1 (10)
Variceal bleeding5 (50)
Ascites6 (60)
Spontaneous bacterial peritonitis1 (10)
Encephalopathy1 (10)
CTP score7.5 (6.75-9.25)
CTP class A2 (20)
CTP class B6 (60)
CTP class C2 (20)
MELD11.5 ± 4.50
MELD-Na16.5 ± 5.12
Table 3 Characteristics of the lymphoma cases, n (%)
Characteristics of lymphomasCases (n = 10)Controls (n = 20)
Lymphoma type and subtypes
Non-Hodgkin lymphoma9 (90)18 (90)
Diffuse large B cell7 (70)17 (85)
Follicular1 (10)0 (0)
Others1 (10)1 (5)
Hodgkin lymphoma1 (10)2 (10)
Nodular sclerosis0 (0)1 (5)
Lymphocyte predominant0 (0)1 (5)
Lymphocyte depleted1 (10)0 (0)
Clinical stages
I1 (10)4 (20)
II2 (20)3 (15)
III1 (10)6 (30)
IV6 (60)7 (35)
Extra nodal involvement6 (60)9 (45)
Prognostic scale
IPI score3 (2.5-3)a2 (1-3)
FLIPI score3-
IPS score32.5
ECOG Performance Status2 (1-2.25)2 (1-2)
B symptoms
Fever3 (30)6 (30)
Weight loss9 (90)11 (55)
Nocturnal diaphoresis4 (40)6 (30)
Helicobacter pylori3 (30)a0 (0)
Table 4 Type of chemotherapy and treatment outcomes, n (%)
ChemotherapyCases (n = 10)Controls (n = 20)
Drugs
Rituximab5 (50)9 (45)
Cyclophosphamide8 (80)17 (85)
Doxorubicin5 (50)15 (75)
Vincristine8 (80)17 (85)
Prednisone6 (60)17 (85)
Bleomycin2 (20)3 (15)
Dacarbazine1 (10)2 (10)
Etoposide4 (40)3 (15)
Vinblastine0 (0)2 (10)
Methotrexate1 (10)4 (20)
Ifosfamide2 (20)2 (10)
Carboplatin2 (20)2 (10)
Dexamethasone2 (20)1 (5)
Others2 (20)4 (20)
Chemotherapy adjustment5 (50)b1 (5)
Radiotherapy1 (10)2 (10)
Treatment response
Complete response4 (40)10 (50)
Partial response4 (40)9 (45)
Stable disease2 (20)1 (5)
Disease progression5 (50)5 (25)
Relapse2 (20)3 (15)
Complications8 (80)18 (90)
Hematologic toxicity6 (60)18 (90)
Gastrointestinal toxicity1 (10)0 (0)
Renal toxicity1 (10)0 (0)
Infectious toxicity1 (10)0 (0)
Decompensating events1 (10)-
Death7 (70)8 (40)
Table 5 Numerical data on the survival of the study population
PopulationMean
Case group (wk)30.66 ± 30.05
Control group (wk)56.46 ± 51.15
Global (wk)44.56 ± 43.76